Loading…
Zhengye Biotechnology Holding Limited is projected to decline to $1.12 by 2027, a -15% move from its current price of $1.33. ZYBT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.17 | $1.33 | $1.52 | -0.05% |
| Aug 6 | $1.10 | $1.33 | $1.60 | -0.10% |
| Aug 7 | $1.06 | $1.33 | $1.67 | -0.15% |
| Aug 8 | $1.02 | $1.33 | $1.72 | -0.20% |
| Aug 9 | $0.9902 | $1.33 | $1.78 | -0.25% |
| Aug 10 | $0.9624 | $1.33 | $1.83 | -0.30% |
| Aug 11 | $0.9375 | $1.33 | $1.87 | -0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9375 | $1.33 | $1.87 | -0.35% |
| Week 2 | $0.8095 | $1.32 | $2.16 | -0.69% |
| Week 3 | $0.7226 | $1.32 | $2.40 | -1.03% |
| Week 4 | $0.6563 | $1.31 | $2.62 | -1.37% |
| Week 5 | $0.6027 | $1.31 | $2.84 | -1.71% |
| Week 6 | $0.5579 | $1.30 | $3.04 | -2.05% |
| Week 7 | $0.5194 | $1.30 | $3.24 | -2.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs.
In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China.
Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
ZYBT is a veterinary vaccine company in the healthcare category. Its current price is $1.36, with a market cap of $64.45M and a rank of 4173. Forecasts show a mixed price outlook through 2026-2030, with neutral to bear sentiment, followed by bullish conditions in 2040 and 2050.
Forecasted averages run from $0.646 in 2026 to $6.59 as a 2050 max, with notable milestones at $2.10 in 2040 and $2.86 in 2050.
A major floor 51.4% below — a decisive break under it would weaken the trend.
The nearest floor, 51.4% below — buyers have tended to step in here.
The nearest ceiling, 502.3% above — a clean break opens room to run.
A major ceiling 704.0% above — clearing it would confirm fresh momentum.
Key ZYBT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZYBT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.36 | Sell | $1.43 | Sell |
| MA 10 | $2.26 | Sell | $1.57 | Sell |
| MA 20 | $1.50 | Sell | $1.50 | Sell |
| MA 50 | $1.08 | Buy | $1.24 | Buy |
| MA 100 | $1.00 | Buy | $1.23 | Buy |
| MA 200 | $1.30 | Buy | $1.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.48 | Neutral |
| Stoch RSI (14) | 13.62 | Buy |
| CCI (20) | -13.26 | Neutral |
| Williams %R (14) | -91.36 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | 77.57 | Buy |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 8.64 | Buy |
| TRIX (15) | 3.48 | Buy |
| Awesome (5,34) | 0.17 | Buy |
| Ultimate (7,14,28) | 49.63 | Neutral |
| Momentum (10) | 0.63 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 1.09 | Buy |
| ADX (14) | 11.16 | Neutral |
| ATR (14) | 0.61 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 50. The stock trades near the SMA50 of $1.07 and the SMA200 of $1.31, with a 30-day range low of $0.4531 and high of $4.08. Support is $0.646 and resistance is $8.01.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.646 | $1.33 | $1.69 | 0% | Neutral | |
| $0.8192 | $1.12 | $1.67 | -15% | Bearish | |
| $0.7677 | $1.12 | $1.77 | -16% | Bearish | |
| $0.6273 | $0.9649 | $1.60 | -27% | Bearish | |
| $0.5689 | $0.9176 | $1.59 | -31% | Bearish | |
| $0.8641 | $1.46 | $2.61 | +10% | Neutral | |
| $0.8595 | $1.51 | $2.80 | +14% | Neutral | |
| $0.7446 | $1.36 | $2.59 | +3% | Neutral | |
| $0.7799 | $1.49 | $2.90 | +12% | Neutral | |
| $0.6288 | $1.25 | $2.48 | -6% | Neutral | |
| $0.9245 | $2.05 | $4.51 | +54% | Bullish | |
| $1.26 | $2.80 | $6.44 | +111% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.646 | $1.33 | $1.61 | +0.00% |
| September 2026 | $1.01 | $1.23 | $1.57 | -7.21% |
| October 2026 | $1.03 | $1.27 | $1.65 | +3.02% |
| November 2026 | $1.05 | $1.31 | $1.73 | +3.38% |
| December 2026 | $1.01 | $1.27 | $1.69 | -3.46% |
Click any year to see its month-by-month ZYBT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ZYBT is projected to trade between $0.646 and $1.69, averaging $1.33 — a potential gain of 0% from today's $1.33. Price action looks broadly range-bound.
Zhengye Biotechnology Holding Limited's 2027 outlook centres on $1.12, within a $0.8192 to $1.67 range. That is -15% versus the projected 2026 average. That marks a -15% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2028, ZYBT could reach as high as $1.77, with a base case around $1.12 and support toward $0.7677 — roughly -16% from $1.33. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect ZYBT to range from $0.6273 to $1.60 through 2029. The $0.9649 average target implies a -27% move from current prices. That is -14% versus the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
The ZYBT price prediction for 2030 points to an average of $0.9176 (low $0.5689, high $1.59) — a potential decline of -31% on today's $1.33. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2031, ZYBT is projected to trade between $0.8641 and $2.61, averaging $1.46 — a potential gain of +10% from today's $1.33. That is up +59% on the projected 2030 average. A consolidation phase looks the most probable path here.
Zhengye Biotechnology Holding Limited's 2032 outlook centres on $1.51, within a $0.8595 to $2.80 range. That is up +4% on the projected 2031 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2033, ZYBT could reach as high as $2.59, with a base case around $1.36 and support toward $0.7446 — roughly +3% from $1.33. A consolidation phase looks the most probable path here.
Expect ZYBT to range from $0.7799 to $2.90 through 2034. The $1.49 average target implies a +12% move from current prices. That is up +9% on the projected 2033 average. Price action looks broadly range-bound.
The ZYBT price prediction for 2035 points to an average of $1.25 (low $0.6288, high $2.48) — a potential decline of -6% on today's $1.33. A consolidation phase looks the most probable path here.
In 2040, ZYBT is projected to trade between $0.9245 and $4.51, averaging $2.05 — a potential gain of +54% from today's $1.33. That is up +65% on the projected 2035 average. Momentum favours further upside here.
Zhengye Biotechnology Holding Limited's 2050 outlook centres on $2.80, within a $1.26 to $6.44 range. That is up +36% on the projected 2040 average. That marks a +111% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZYBT today (≈ 751.879699 ZYBT) could be worth
$2,106.72
+$1,106.72 (+111%) by 2050 · US Dollar
Based on the average projected ZYBT price of $2.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZYBTwould be worth at today's price.
$1,000 invested in ZYBT on Jul 31, 2025 (≈ 180.83182 ZYBT) would be worth
$240.51
-$759.49 (-75.9%) today · 0.24× · US Dollar
Based on a ZYBT entry price of $5.53 vs. today's $1.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.73 | $768.79 | -23.1% |
| 1 month ago | $0.677 | $1,964.55 | +96.5% |
| 3 months ago | $0.92 | $1,445.65 | +44.6% |
| 6 months ago | $0.94 | $1,414.89 | +41.5% |
| 1 year ago | $5.53 | $240.51 | -75.9% |
| All time (1.6y) ago | $4.86 | $273.66 | -72.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZYBT forecast.
Our base-case forecast reaches $2.70 around 2050.
Implied market cap at $2.70: $127.96M
The multi-year forecast shows a bearish path through 2030, with 2030 avg $0.9497, min $0.5885 and max $1.64, and ROI of -30.2% (sentiment BEARISH). From 2031 to 2035, the averages move higher, with 2031 avg $1.49 and 2032 avg $1.54, 2033 avg $1.40, 2034 avg $1.52, and 2035 avg $1.27, with ROI values of 9.7%, 13.1%, 2.9%, 11.8%, and -6.7% respectively (sentiment NEUTRAL for these years). In 2040 the forecast turns bullish with avg $2.10, ROI 54.2%, sentiment BULLISH; and in 2050 it remains bullish with avg $2.86, ROI 110.5%, sentiment BULLISH.
These are estimates and not guarantees, reflecting potential upside if the trajectory plays out, along with the inherent risks of volatility in the sector.
Tap a question to reveal the answer.
Avg price $0.9497, min $0.5885, max $1.64; ROI -30.2%; sentiment BEARISH.
Forecasts show a neutral outlook in 2026 (avg $1.36) and negative ROI through 2030, with bullish later years (2040 avg $2.10, ROI 54.2; 2050 avg $2.86, ROI 110.5). There is no guarantee of gains.
Yes—the max forecast for 2050 is $6.59.
Current price is $1.36 and market cap is $64.45M.
RSI14 is 50; SMA50 is $1.07; SMA200 is $1.31; 30-day range is $0.4531 to $4.08; support is $0.646 and resistance is $8.01; sentiment is NEUTRAL.
Zhengye Biotechnology Holding Limited Community Discussion
0Share your Zhengye Biotechnology Holding Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.